4D Molecular Therapeutics, Inc. Stock price

Equities

FDMT

US35104E1001

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:45:31 2024-03-28 pm EDT 5-day change 1st Jan Change
32.32 USD -9.90% Intraday chart for 4D Molecular Therapeutics, Inc. -3.61% +60.81%
Sales 2024 * 6.35M Sales 2025 * 7.38M Capitalization 1.79B
Net income 2024 * -153M Net income 2025 * -186M EV / Sales 2024 * 205 x
Net cash position 2024 * 482M Net cash position 2025 * 321M EV / Sales 2025 * 198 x
P/E ratio 2024 *
-11.7 x
P/E ratio 2025 *
-10.5 x
Employees 147
Yield 2024 *
-
Yield 2025 *
-
Free-Float 83.06%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : 4D Molecular Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:30 AM
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
4D Molecular Therapeutics, Inc. Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium? 2024 CI
4d Molecular Therapeutics Insider Sold Shares Worth $737,788, According to a Recent SEC Filing MT
4D Molecular Therapeutics Launches $250 Million Stock Offering MT
4D Molecular Therapeutics Shares Surge on Positive Data From Phase 2 Study of Wet AMD Drug Candidate MT
Top Midday Gainers MT
BMO Capital Adjusts 4D Molecular Therapeutics' Price Target to $70 From $50, Keeps Outperform Rating MT
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes' RE
Powell Comments Dampen Near-Term Rate Cut Hopes, Stifling US Equity Futures Pre-Bell MT
RBC Raises PT on 4D Molecular Therapeutics to $35 From $25, Keeps Outperform Rating, Speculative Risk MT
Transcript : 4D Molecular Therapeutics, Inc. - Special Call
Top Premarket Gainers MT
4D Molecular Therapeutics Presents Positive Interim Data from Randomized Phase 2 Prism Clinical Trial of Intravitreal 4D-150 CI
4D Molecular Therapeutics' Treatment Candidate for Cystic Fibrosis Gets FDA Rare Pediatric Disease Designation MT
More news
1 day+5.35%
1 week+7.07%
Current month+28.02%
1 month+19.93%
3 months+70.00%
6 months+175.50%
Current year+77.05%
More quotes
1 week
32.90
Extreme 32.9
36.25
1 month
27.00
Extreme 27
36.25
Current year
16.64
Extreme 16.64
36.25
1 year
9.44
Extreme 9.44
36.25
3 years
5.32
Extreme 5.32
44.03
5 years
5.32
Extreme 5.32
55.11
10 years
5.32
Extreme 5.32
55.11
More quotes
Managers TitleAgeSince
Founder 49 13-09-11
Founder 62 13-09-11
Director of Finance/CFO - 23-09-11
Members of the board TitleAgeSince
Chairman 63 20-07-31
Director/Board Member 63 20-06-30
Director/Board Member 60 15-12-31
More insiders
Date Price Change Volume
24-03-28 32.53 -9.31% 851 345
24-03-27 35.87 +5.35% 723,668
24-03-26 34.05 +1.34% 487,821
24-03-25 33.6 0.00% 297,482
24-03-22 33.6 -0.59% 302,108

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
4D Molecular Therapeutics, Inc. is a clinical-stage biotherapeutics company. The Company is developing a diverse pipeline of product candidates for both large market and rare diseases, including patient populations that other genetic medicines are unable to address. The Company's initial product candidates are focused on therapeutic areas, such as ophthalmology, pulmonology, and cardiology. The Company's five product candidates include 4D-150, 4D-710, 4D-125, 4D-110, and 4D-310. 4D-150 is used for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). 4D-710 is used for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations). 4D-310 is used for the treatment of Fabry disease cardiomyopathy. 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP). 4D-110 is used for the treatment of choroideremia.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
35.87 USD
Average target price
50.11 USD
Spread / Average Target
+39.70%
Consensus
  1. Stock
  2. Equities
  3. Stock 4D Molecular Therapeutics, Inc. - Nasdaq